NEW YORK–(BUSINESS WIRE)–Tactical Therapeutics, Inc., a clinical stage oncology drug development company, announced today it is scheduled to present study results of its lead drug Carboxyamidotriazole Orotate (CTO) at the annual American Society of Clinical Oncology meeting taking place May 29th to June 2nd in Chicago, Illinois. The poster will be presented by the investigators on Monday […]

New York, April 2, 2015, — Tactical Therapeutics, Inc., a clinical stage oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10th to May 14th in La Jolla, California. The purpose of the Forum is to help family offices and foundations develop and implement their […]

Pre-clinical studies suggest carboxyamidotriazole orotate (CTO) demonstrates anti-tumor activity through modulation of multiple tyrosine kinase signaling pathways and interactions with the tu- mor microenvironment. We determined the safety and tolerability, pharmacokinetic profile, maximum tolerated dose, and recommended Phase II dose of CTO monotherapy in patients with advanced solid tumors. In this first-in-human Phase I clinical […]

One thing is certain about cancer treatment: The active ingredient must achieve high concentrations in the brain – without causing unacceptable toxicity in the patient. That’s an especially tricky balance to achieve in treating gliomas and glioblastomas; that’s because the treatment compound must cross the blood brain barrier to reach the tumor target; otherwise patient survival […]

Dynamic contrast-enhanced magnetic resonance perfusion weighted imaging (DCE-MRI) and diffusion weighted imaging (DWI) for pharmacodynamic evaluation of CTO and temozolomide in malignant glioma

Phase IB Trial of Carboxyamidotriazole Orotate (CTO) and Temozolomide for Recurrent Malignant Glioma (MG): A Novel Mechanism for Modulation of Multiple Oncogenic pathways

A Phase I Study of Carboxyamidotriazole Orotate (CTO) in Treatment of Advanced Solid Tumors